High Deep-Remission Rate With Triple Regimen for Relapsed/Refractory CLL

Undetectable disease rate over 90%, ctDNA also promising for earlier detection of recurrence

Related Keywords

Germany ,United States ,American ,Charles Bankhead ,Richard Larson ,University Of Chicago ,University Of Cologne ,American Society Of Hematology ,American Society ,Medpage Today ,